Krystal Biotech to Present at Upcoming Investor Conferences
27 nov. 2024 07h00 HE
|
Krystal Biotech, Inc.
PITTSBURGH, Nov. 27, 2024 (GLOBE NEWSWIRE) -- Krystal Biotech, Inc. (the “Company”) (NASDAQ: KRYS), a commercial-stage biotechnology company, today announced that Krish S. Krishnan, Chairman and...
Krystal Biotech to Present at Stifel 2024 Healthcare Conference
12 nov. 2024 07h00 HE
|
Krystal Biotech, Inc.
PITTSBURGH, Nov. 12, 2024 (GLOBE NEWSWIRE) -- Krystal Biotech, Inc. (the “Company”) (NASDAQ: KRYS), a commercial-stage biotechnology company, today announced that the Company will participate in the...
Krystal Biotech to Present at Guggenheim Securities Healthcare Innovation Conference
06 nov. 2024 07h00 HE
|
Krystal Biotech, Inc.
PITTSBURGH, Nov. 06, 2024 (GLOBE NEWSWIRE) -- Krystal Biotech, Inc. (the “Company”) (NASDAQ: KRYS), a commercial-stage biotechnology company, today announced that the Company will participate in the...
Krystal Biotech Announces Third Quarter 2024 Financial Results and Provides Business Updates
04 nov. 2024 08h00 HE
|
Krystal Biotech, Inc.
Net product revenue of $83.8 million in 3Q and $250.1 million since launch in August 2023 JNDA for B-VEC filed and on track for commercial launches in Japan and Europe in 2025 French health...
Krystal Biotech to Report Third Quarter 2024 Financial Results on November 4, 2024
28 oct. 2024 07h00 HE
|
Krystal Biotech, Inc.
PITTSBURGH, Oct. 28, 2024 (GLOBE NEWSWIRE) -- Krystal Biotech, Inc. (the “Company”) (NASDAQ: KRYS), a commercial-stage biotechnology company, today announced that it will report its third quarter...
Krystal Biotech to Present at 2024 Cantor Global Healthcare Conference
13 sept. 2024 07h00 HE
|
Krystal Biotech, Inc.
PITTSBURGH, Sept. 13, 2024 (GLOBE NEWSWIRE) -- Krystal Biotech, Inc. (the “Company”) (NASDAQ: KRYS), a commercial-stage biotechnology company, today announced that the Company will participate in...
Krystal Biotech to Present at H.C. Wainwright 26th Annual Global Investment Conference
06 sept. 2024 07h00 HE
|
Krystal Biotech, Inc.
PITTSBURGH, Sept. 06, 2024 (GLOBE NEWSWIRE) -- Krystal Biotech, Inc. (the “Company”) (NASDAQ: KRYS), a commercial-stage biotechnology company, today announced that the Company will participate in...
Jeune Aesthetics Announces Phase 1 Positive Interim Safety and Efficacy Results for KB301 in the Treatment of Lateral Canthal Lines and Dynamic Wrinkles of the Décolleté
28 août 2024 07h00 HE
|
Krystal Biotech, Inc.
Décolleté indication selected for Phase 2 study expected to start next year Conference call to discuss results scheduled for Wednesday, August 28, 2024 at 4:30 p.m. ET PITTSBURGH, Aug. 28, 2024...
Krystal Biotech Announces Second Quarter 2024 Financial Results and Provides Business Updates
05 août 2024 08h00 HE
|
Krystal Biotech, Inc.
Net product revenue of $70.3 million in 2Q and $166.2 million since launch in August 2023 On track to deliver three clinical readouts in 2H 2024Jeune Aesthetics’ KB301 Phase 1...
Krystal Biotech to Report Second Quarter 2024 Financial Results on August 5, 2024
26 juil. 2024 08h00 HE
|
Krystal Biotech, Inc.
PITTSBURGH, July 26, 2024 (GLOBE NEWSWIRE) -- Krystal Biotech, Inc. (the “Company”) (NASDAQ: KRYS), a commercial-stage biotechnology company, today announced that it will report its second quarter...